Home » Stocks » PRTA

Prothena Corporation PLC (PRTA)

Stock Price: $11.27 USD -0.22 (-1.91%)
Updated Oct 28, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 449.80M
Revenue (ttm) 797,000
Net Income (ttm) -90.85M
Shares Out 39.91M
EPS (ttm) -2.28
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 28, 2020
Last Price $11.27
Previous Close $11.49
Change ($) -0.22
Change (%) -1.91%
Day's Open 11.35
Day's Range 11.01 - 11.43
Day's Volume 137,892
52-Week Range 7.10 - 17.63

More Stats

Market Cap 449.80M
Enterprise Value 131.00M
Earnings Date (est) Nov 4, 2020
Ex-Dividend Date n/a
Shares Outstanding 39.91M
Float 39.89M
EPS (basic) -2.28
EPS (diluted) -2.28
FCF / Share -1.65
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.34M
Short Ratio 4.23
Short % of Float 3.36%
Beta 1.84
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 564.36
PB Ratio 2.01
Revenue 797,000
Operating Income -95.83M
Net Income -90.85M
Free Cash Flow -65.72M
Net Cash 318.79M
Net Cash / Share 7.99
Gross Margin -6,276.29%
Operating Margin -12,023.34%
Profit Margin -11,399.40%
FCF Margin -8,245.67%
ROA -14.24%
ROE -33.82%
ROIC -202.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (6)

Buy 2
Overweight 0
Hold 3
Underweight 1
Sell 0

Analyst Consensus: Overweight

Price Target

(38.42% upside)
Current: $11.27
Target: 15.60
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-14.76%-96.53%2508.44%-34.35%-96.84%7422.78%-74.57%424.26%-59.21%-
Gross Profit0.810.9627.521.061.6150.850.682.660.511.24
Operating Income-85.70-159-155-160-79.94-6.65-40.43-41.41-29.24-12.16
Net Income-77.68-156-153-160-80.61-7.15-41.00-41.41-29.67-12.48
Shares Outstanding39.8839.5637.6534.3530.3324.6718.6214.5914.5014.50
Earnings Per Share-1.95-3.93-4.07-4.66-2.66-0.29-2.20-2.84-2.05-0.86
Operating Cash Flow-52.97-28.28-131-116-58.60-0.68-32.10-42.07-19.70-9.08
Capital Expenditures-0.55-1.73-3.52-16.64-1.38-0.50-0.54-1.30-0.60-2.61
Free Cash Flow-53.52-30.01-135-133-59.98-1.18-32.63-43.37-20.29-11.69
Cash & Equivalents376428418387371294177125--
Total Debt17.84---------
Net Cash / Debt358428418387371294177125--
Book Value273323407365361290173126-6.440.10
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Prothena Corporation PLC
Country Ireland
Employees 51
CEO Gene G. Kinney

Stock Information

Ticker Symbol PRTA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: PRTA


Prothena Corporation plc, a clinical-stage neuroscience company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, an antibody that is in Phase I clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia, chronic traumatic encephalopathy, and other tauopathies; Aß, or Amyloid Beta, a protein for the treatment of Alzheimer's disease; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and other products for neurodegeneration. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. Prothena Corporation plc was founded in 2012 and is based in Dublin, Ireland.